Enterprise Value
861.4M
Cash
132.1M
Avg Qtr Burn
-28.56M
Short % of Float
9.37%
Insider Ownership
3.78%
Institutional Own.
91.98%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LIVMARLI (Maralixibat) Details Alagille syndrome, Chronic pruritus | Approved Quarterly sales | |
LIVMARLI (Maralixibat) Details Liver disease, Progressive familial intrahepatic cholestasis | PDUFA Approval decision | |
Volixibat (VANTAGE) Details Primary biliary cholangitis, Liver disease | Phase 2b Interim update | |
Volixibat (VISTAS) Details Liver disease, Primary sclerosing cholangitis | Phase 2b Interim update | |
LIVMARLI (Maralixibat) Details Rare diseases, Bile duct disease Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2 Data readout | |
Volixibat (OHANA) Details Liver disease, Intrahepatic Cholestasis of Pregnancy | Failed Discontinued |